From: The role of MMP-14 in ovarian cancer: a systematic review
Author | Tumour samples | Selection of samples | Years | Country | Scoring system | Number of patients or samples | Result MMP-14 | Percentage positive | Conclusion |
---|---|---|---|---|---|---|---|---|---|
Sakata et al. [56] | Primary tumours | Selection from archive UHa | n.m | Japan | 0–5% = 0, 5–50% = 1, > 50% = 2 | 114 | 0 benign, 5 borderline, 59 malignant | 76% | More MMP-14 expression in tumours with lymphnode metastasis |
Torng et al. [64] | Primary tumours, serous and endometroid | Selection from archive UHa | 1993–2000 | Taiwan |  |  | positive, numbers n.m.b |  | Expression MMP-14 and MMP-2 correlates |
Kamat et al. [57] | Primary tumours | Selection from archive UHa | 1990–2000 | USA | Overall Score | 90 | 90 epithelial | 100, moderate 56%, strong 44% | HRc epithelial MMP-14 2,52 (1.30–4.88) |
 |  |  |  |  |  |  | 87 stromal | 97 (62% low, 38% high) | HRc stromal MMP-14 1,30 (1.03–3.39) |
 |  |  |  |  |  |  |  |  | Both MMP-14 epithelial and stromal expression correlates with survival |
Lin et al. [59] | Primary tumours | Selection from archive UHa | n.m | USA |  | 77 |  | 44% epithelial expression | Strong epithelial MMP-14 expression > 3 risk of death p 0.003 |
 |  |  |  |  |  |  |  | 40% stromal expression |  |
Barbolina et al. [38] | Primary tumours | Selection from archive UHa | n.m | USA | Â | 149 | Â | 78%, 52% high, 94% in clear cell carcinomas | No relation with stage |
Adley et al. [26]d | Primary tumours | Selection from archive UHa | 1999–2003 | USA |  | 143 | 77 | 54 | 32/70 serous, 23/44 endometroid, 5/9 mucinous, 17/18 clear cell |
Paulsen et al. [63] | Primary serous borderline tumours and implants | Selection from Cancer Registry (total 632) | 1985–1995 | Norway |  | Serous borderline tumours | 7 moderate, 33 strong/44, 4 weak, 8 moderate, 42 strong/55 |  | No difference between group with and without implants, all 7 recurrences positive |
Brun et al. [60] | Primary serous and mucinous tumours | Selection from archive UHa | 2001–2006 | France | HSCORE | Serous | 115 | benign/borderline 99/95, malignant 134 |  |
 |  |  |  |  |  | Mucinous | 44 |  |  |
Kato and Motoyama [65] | Primary clear cell and serous carcinomas | Selection from archive UHa | 1997–2007 | Japan |  | 30 clear cell carcinomas | 22 | 73 | No relation with stage or survival |
 |  |  |  |  |  | 30 serous carcinomas | 1 | 3 |  |
Wang et al. [78] | Primary tumours and metastasis | Selection from archive UHa | 2001–2006 | China |  |  |  | positive, numbers n.m.c | Colocalization with uPA, numbers not given |
Moss et al. [32] | Primary tumours and metastasis | Selection from archive UHa | n.m.b | USA | 0–3 | 15 serous primary | 5 weak, 9 moderate, 1 strong | 67 |  |
 |  |  |  |  |  | 15 serous metastasis | 4 weak, 9 moderate, 2 strong | 73 | Only 2 metastasis had less expression than the primary tumour |
 |  |  |  |  |  | 2 endometroid | 1 weak | 50 |  |
 |  |  |  |  |  | 2 endometroid metastasis | 2 moderate | 100 |  |
Brun et al. [60] | Primary tumours | Consecutive series UHa FIGO III-IV | 2001–2006 | France | HSCORE | 43 primary surgery | 132 epithelial/12 stromal |  | No independent prognosticator |
 |  |  |  |  |  | 26 interval surgery | 97 epithelial/8 stromal |  |  |
Bruney et al. [49] | Cores of ovarian adenocarcinomas | N.m.b | n.m | USA | Â | 50 | positive, numbers n.m.b | Â | Inverse relationship with MUC16/CA 125 |
Nakayama et al. [74] | Primary tumours | Selection from archive UHa | 2005–2011 | Japan |  | 68 | 12 | 18 |  |
Trudel et al. [79] | Primary tumours | Selection from archive UHa | 1993–2006 | Canada | Visual score HSCORE | 160/170 | 105 | 66 | No independent prognosticator |
Bruney et al. [48]e | Cores of ovarian adenocarcinomas | N.m.b | n.m | USA | Â | 46 | positive, numbers n.m.b | Â | Â |
Vos et al. [61] | Primary tumours | Consecutive series archives teaching hospital | 1997–2003 | the Netherlands | Overall Score | 94 | 53 positive epithelial | 56 | No independent prognosticator |
 |  |  |  |  |  |  | 49 positive stromal | 52 |  |
Vos et al. [62] | Primary tumours | Consecutive series archives clinical network | 2007–2008 | the Netherlands | Overall Score | 97 | 52 positive epithelial | 54 |  |
 |  |  |  |  |  |  | 5 positive stromal | 5 |  |
Takahashi et al. [80] | Primary tumours | Selection from archive UHa | 2000–2014 | Japan | Visual and computer-supported evaluation | 107 carcinoma's, 54 borderline, 45 benign | positive, numbers n.m.b |  | In-situ proximity assay for EphA2 and MMP-14 positive |
Vos et al. [58] | Primary tumours and haematogenic and lymphogenic metastasis | Consecutive series archives teaching hospital | 2000–2015 | the Netherlands | Overall Score | 44 | 37 primary tumours positive/7 missing | 37/44 | Most metastasis also positive |
 |  |  |  |  |  |  | 34 positive stromal/3 negative stromal/7 missing |  |  |